Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RE-MODEL (Thromboembolism Prevention After Knee Surgery). Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With a Half Dose (i.e.75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 6-10 Days

NCT00168805 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00168805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00168805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RE-MODEL (Thromboembolism Prevention After Knee Surgery). Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With a Half Dose (i.e.75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 6-10 Days
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2004
Completion date
Not reported
Enrollment
2,101 (actual)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

arthroplasty, replacement, knee, thromboembolism